Order momentum meets execution test — Q2 signals capacity push
Garden Reach faces a key test of its defence order execution pipeline after strong Q1. With ₹2,896 Cr capex approved for a greenfield shipyard and recent order wins exceeding ₹1,100 Cr, the quarter will reveal whether the company can sustain 38%+ revenue growth while absorbing heavy capex. Street expects solid momentum, but execution delays remain the consensus caution.
What to expect — the metrics
~₹1,950–₹2,000 Cr
Implied 33–37% YoY growth, vs Q1's 38.5%. Run-rate holds if order execution stays on track; any slip triggers miss.
~9–10%
In line with Q1's 9.5% absolute (₹173 Cr). Capex absorption and increased depreciation are the pressure points.
₹1,100+ Cr fresh wins (Q3 to date)
ONGC PSVs ₹1,032 Cr, WBTDCL ferries ₹45 Cr, SPML tug ₹37.9 Cr LOI. Pipeline health intact, but execution timing is the Street debate.
₹2,896 Cr Raichak approval
Board cleared greenfield shipyard project (Sep 21). This is transformational but creates near-term FCF headwind and execution risk.
A strong Q2 would show revenue growth of 35%+ YoY, PAT margins holding at 9% or better, and management guiding confidently on Raichak construction timeline and full-year execution. A weak Q2 would signal deceleration (growth below 30%), margin compression (under 8.5%), and any guidance cuts or defence order delays flagged on the call.
On track? The run-rate vs FY27 guide
Q1 FY27 delivered ₹1,815 Cr revenue (+38.5% YoY) and ₹173 Cr PAT (+43.8% YoY), setting a brisk pace toward the FY27 analyst consensus of ₹8.39k Cr revenue (+19.9%) and ₹76.95 EPS (+17.9%). For the full-year guide to hold at that +20% midpoint, Q2–Q4 must average around ₹1,800–₹1,900 Cr per quarter. If Q2 misses (say, ₹1,700 Cr), the FY27 reset would be material. Management's conduct of the call — confidence on Raichak capex and defence order finalization — will be the read.
What the Street says
Since last quarter — the event scan
1 · Greenfield capex approval (Sep 21)
Board cleared ₹2,896 Cr for Raichak shipyard project — the headline capex event. This is strategic (diversifies away from Kolkata location risk and adds 30% capacity), but is transformational: management must now detail timeline, funding plan (capex vs debt), and IRR expectations on the Q2 call. Any delays flagged would reset the re-rate narrative.
2 · Order wins and MoU signings (Aug–Sep)
ONGC PSVs ₹1,032 Cr (Jul 30), WBTDCL ferries ₹45 Cr (Aug 24), SPML tug ₹37.9 Cr LOI (Aug 4), plus MoUs with DNV (warship design) — signals healthy order pipeline. However, Antique's recent caution on finalization delays suggests backlog growth is decelerating; watch whether Q2 adds new LOIs or conversions.
3 · Governance changes (Oct 6, Oct 16)
Appointed Dharminder Kumar and Laishram Meenabanta Singh as Independent Directors. New statutory auditor (M/s. S K Agarwal & Co.). Routine governance churn; no red flags flagged.
4 · Dividend (Sep 3)
FY26 final dividend ₹6.70 per share. Capital allocation remains investor-friendly; no surprise, as promoter ownership is stable at 74.5% and FII at 3.22% (down 0.29pp QoQ, a mild sell-off since Q1).
Key watch points for result day (Nov 4)
1 · Order execution pace & backlog health
Is the ₹1,032 Cr ONGC order moving to production? Are there new LOI conversions? Management's color on finalization timelines for defence orders (Antique's cited caution) will set the tone for FY27 guidance confidence.
2 · Raichak capex — timeline and funding
How is the ₹2,896 Cr greenfield being phased? Debt vs equity mix? Expected production ramp? Any capex pressure on dividends or FCF? This is the session's strategic anchor.
3 · Margin sustainability
Q2 absolute margin vs Q1's 9.5%. Will depreciation from greenfield capex (even if phased over years) crimp profitability in FY27–FY28? Any guidance on medium-term margin targets?
4 · Full-year FY27 guidance — re-affirm or reset?
Q1's strong start set a high bar for the analyst consensus (₹8.39k Cr, ₹76.95 EPS). If Q2 misses, will management cut FY27 or re-affirm and flag a back-loaded H2? Any reset would explain (and justify) the 57% gap between current price and analyst targets.
GRSE's Q2 print arrives amid a classic tension: Q1 delivered explosive growth (38.5% revenue, 43.8% PAT), but the stock is trading 46% below its all-time high and 37% below the median analyst target. The disconnect is execution risk — Antique cut targets citing defence order finalization delays, and one analyst remains a Seller. The ₹2,896 Cr Raichak greenfield approval is transformational, but it's also a capex load that must be justified by order pipeline depth and margin durability.
On result day, the narrative hinges on three items: (1) does revenue growth sustain above 33% YoY, or does it slip toward 25–30% (a miss signal)? (2) can management detail a credible Raichak timeline and funding plan without crushing near-term FCF? (3) will management re-affirm or cut full-year guidance? A solid beat on execution pace, margin hold at 9%+, and confident FY27 guidance could spark a re-rate closer to the ₹2,987 consensus target. A miss or caution would deepen the bears' thesis and extend the 46% discount from ATH.
Informational and educational content only. Not investment advice.